Basilea Pharmaceutica Ltd (BSLN)
SIX
Closed
Oct 7, 2026
Day's Range
64.1052 wk Range
44.70Overview - BSLN - Basilea Pharmaceutica Ltd
Key Statistics
Valuation
Enterprise Value
762.47M
P/E (Trailing)
‪17.13‬
P/E (Forward)
‪14.98‬
PEG Ratio
‪14.98‬
Price / Sales (TTM)
‪3.44‬
Price / Book
‪5.24‬
EV / EBITDA
‪12.51‬
Profitability
Profit Margin
‪21.17%‬
Operating Margin
‪26.89%‬
Return on Assets
‪13.68%‬
Return on Equity
‪39.45%‬
Ownership
Shares Outstanding
12.37M
Float
11.31M
Held by Insiders
‪0.61%‬
Held by Institutions
‪31.42%‬
Price stats
Beta
‪0.43‬
50-Day Avg
‪59.62‬
200-Day Avg
‪55.16‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
4 analysts
Average price target
‪CHF 88.50‬Market Cap - BSLN - Basilea Pharmaceutica Ltd
Peers - BSLN - Basilea Pharmaceutica Ltd
Peer Comparison
Compared with companies in Biotechnology listed on SIX.
- BSLNSIXBasilea Pharmaceutica Ltd851.32MMarket Cap+32.82%52-week change17.13P/E (Trailing)‪21.17%‬Profit Margin
- BIONSIXBB Biotech AG3.08BMarket Cap+42.23%52-week change2.29P/E (Trailing)‪127.31%‬Profit Margin
- BIOVSIXBioVersys AG153.39MMarket Cap-8.78%52-week change-6.84P/E (Trailing)‪-386.62%‬Profit Margin
- ADXNSIXAddex Therapeutics Ltd3.73MMarket Cap-145.53%52-week change-0.41P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - BSLN - Basilea Pharmaceutica Ltd
About
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company headquartered in Allschwil, Switzerland, founded in 2000 as a spin-off from F. Hoffmann-La Roche. With approximately 150 employees, it focuses on discovering, developing, and commercializing innovative anti-infective drugs to address severe…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
